Percheron Therapeutics (ASX:PER) has entered into a worldwide exclusive license agreement with Hummingbird Bioscience, a venture-backed biotechnology company based in Singapore, for HMBD-002, a monoclonal antibody therapy with potential applications in various cancer indications. …
Percheron licenses Phase 2 ready immuno-oncology candidate from Hummingbird
June 27, 2025 Australian Biotech
Latest Video
New Stories
-
The Dispatched 'Week in Review' Podcast - 27 June
June 27, 2025 - - Podcast -
Percheron licenses Phase 2 ready immuno-oncology candidate from Hummingbird
June 27, 2025 - - Australian Biotech -
PYC Therapeutics to present progress in Phelan-McDermid Syndrome at global congress
June 27, 2025 - - Australian Biotech -
Atmo Biosciences receives US FDA clearance for ingestible gas-sensing capsule
June 27, 2025 - - Australian Biotech -
Hospital pharmacists use Rare Cancers Awareness Day to call for reform
June 27, 2025 - - Latest News -
MedAdvisor progressing review, including the potential sale of ANZ business
June 27, 2025 - - Latest News -
Mark Butler retains position on critical Cabinet committee
June 26, 2025 - - Latest News